Neurocrine Biosciences Articles

UK’s NICE turns down GlaxoSmithKline’s Revolade, as drugmaker and Neurocrine’s antidepressant fails in Ph II

15 September 2010

Neurocrine signs licensing deal worth up to $235 million with Boehringer for diabetes drug GPR119, hot on the heels of Abbott accord

18 June 2010

Abbott in $575 million deal for rights to Neurocrine’s elagolix for the treatment of endometriosis

17 June 2010

Showing 1-3 of 3 articles

Go to beginning

Previous

1

Next

Go to end